Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate

What is already known about this subject • Mometasone furoate (MF) is a new inhaled glucocorticoid for which the first reports suggested a low degree of systemic side‐effects and low systemic availability. • Recent studies of Fardon and colleagues have shown that MF's cortisol suppression is si...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2007-11, Vol.64 (5), p.698-705
Hauptverfasser:	Tayab, Zia R., Fardon, Tom C., Lee, Daniel K. C., Haggart, Kay, McFarlane, Lesley C., Lipworth, Brian J., Hochhaus, Günther
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adult Aged Androstadienes - administration & dosage Androstadienes - metabolism Androstadienes - pharmacokinetics Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - metabolism Anti-Inflammatory Agents - pharmacokinetics Biological and medical sciences Female Fluticasone fluticasone propionate Humans Hydrocortisone - urine Male Medical sciences Middle Aged Mometasone Furoate Pharmacology. Drug treatments plasma protein binding Pregnadienediols - administration & dosage Pregnadienediols - metabolism Pregnadienediols - pharmacokinetics Protein Binding - drug effects pulmonary deposition Respiratory system Short Reports systemic side‐effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!